Agilent that it has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to aid in identifying patients with synovia...
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment ...
Kiromic BioPharma, reports favorable eight-month follow-up results from the first patient enrolled in its Deltacel-01 Phase 1 clinical trial. This trial ...
Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leadin...
In a recent Q&A session with BioPharma BoardRoom, Gavin Kurgan, Bioinformatics Applications Development Manager at Integrated DNA Technologies ...
Oxford Nanopore Technologies, the company behind a new generation of molecular sensing technology based on nanopores, and Plasmidsaurus, the LA-based com...
Pfizer Inc. announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gen...
GC Cell Corporation (hereinafter referred to as "GC Cell"; 144510:KOSDAQ) and Lukas Biomedical Co., Ltd. (hereinafter referred to as "Lukas," TWSE ...
Integrated DNA Technologies (IDT), a global leader in CRISPR genome editing solutions, inked a licensing agreement with SeQure Dx, a company focused on off...
Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced that it has receive...
Global biotechnology leader CSL Behring announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dez...
Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, announces the decision to transfer its eosinoph...
Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, today announced the launch of Celselect Slides 2....
SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today anno...
© 2024 Biopharma Boardroom. All Rights Reserved.
